Top Markets
Coin of the day
Definium Therapeutics, Inc. Definium Therapeutics, Inc.

Definium Therapeutics, Inc.

DFTX
株式のランク #3214
Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm... Definium Therapeutics, Inc. operates as a clinical-stage biopharmaceutical firm dedicated to developing innovative therapeutic solutions for various brain health and neurological disorders. Its pipeline features key experimental drug candidates like MM120, which is currently undergoing Phase 3 clinical trials for generalized anxiety disorder (GAD) and attention deficit hyperactivity disorder (ADHD). Another significant compound, MM402 – an R-enantiomer of 3,4-methylenedioxymethamphetamine – is in Phase 1 trials, targeting the fundamental symptoms of autism spectrum disorder. The company maintains its headquarters in New York, New York.
株価
$44.42
最終同期: 2026-08-25
時価総額
$5.90B
変化(1日)
2.66%
変化(1年)
344.66%
US
取引 Definium Therapeutics, Inc. (DFTX)

カテゴリー

Definium Therapeutics, Inc.(DFTX)の配当利回りの履歴
Definium Therapeutics, Inc.(銘柄コード: DFTX)の配当利回り(TTM)は2026時点で0です。
過去5年間の平均配当利回り: 0.00%
Definium Therapeutics, Inc.(DFTX)の2026から2026までの配当利回りの履歴
各年末時点の配当利回り(TTM)
配当利回り 変化
提供された日付のデータは十分ではありません。
類似企業または競合他社の配当利回り(TTM)